Compare STRO & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRO | QTRX |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | 131 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.9M | 306.0M |
| IPO Year | N/A | 2017 |
| Metric | STRO | QTRX |
|---|---|---|
| Price | $25.64 | $3.54 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $26.38 | $8.00 |
| AVG Volume (30 Days) | 159.8K | ★ 779.0K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | $13.45 | $9.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $0.52 | $3.36 |
| 52 Week High | $27.96 | $8.77 |
| Indicator | STRO | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 29.07 |
| Support Level | $0.76 | $3.36 |
| Resistance Level | $27.96 | $5.56 |
| Average True Range (ATR) | 2.13 | 0.31 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 90.81 | 11.15 |
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.